References

Filters: Author is Feng, HP  [Clear All Filters]
F
Feng HP, Guo Z, Caro L, et al. Assessment of drug interaction potential between the hepatitis C virus direct-acting antiviral agents elbasvir/grazoprevir and the nucleotide analog reverse-transcriptase inhibitor tenofovir disoproxil fumarate. Clin Pharmacol Drug Dev. 2019;8(7):962-970.
Feng HP, Guo Z, Fandozzi C, et al. Pharmacokinetic interactions between the fixed-dose combinations of elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine and elbasvir/grazoprevir in healthy adult participants. Clin Pharmacol Drug Dev. 2019;8(7):952-961. doi:10.1002/cpdd.702.
Feng HP, Caro L, Dunnington KM, et al. A clinically meaningful drug-drug interaction observed between Zepatier (Grazoprevir/Elbasvir) and Stribild HIV fixed dose combination in healthy subjects [Abstract O-22]. In: International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy. June 8-10. International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy. June 8-10.; 2016.
Feng HP, Guo Z, Ross L, et al. Assessment of drug interaction potential between the direct-acting antiviral agents elbasvir/grazoprevir and integrase inhibitors raltegravir and dolutegravir. J Antimicrob Chemother. 2019;74(3):710-717.
Top